Safety and Tolerability of Ribavirin (RO 20-9963) in Combination With Peginterferon Alfa-2a (40 kD)in Patients With Chronic Hepatitis C
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Roche
- 23 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Apr 2013 Planned end date changed from 1 Apr 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 15 Aug 2012 Actual patient number changed from 7725 to 7727 as reported by ClinicalTrials.gov.